There are a few that conclude the radiosensitization effects of CDK4/6 inhibitors, although not in every tumor type, mainly in HPV-positive, high-mitotic activity, and head and neck squamous cell cancer, whose biological features are different from relatively slow-growing hormone receptor-positive breast cancers. The gene discussed is CDK4; the disease is neoplasm.